← All medications

Insulin degludec

Medication ultra-long-acting insulin diabetes
Aka: Tresiba
Brands seen in Singapore: Tresiba
Not medical advice. Check with your doctor or pharmacist before you start, stop or change the timing of anything you take.
How to use
What it’s for
SG label: diabetes mellitus in adults and ages 12–17
When to take
SG label: once daily, any time of day, preferably the SAMe
Take with
Injected under the skin — thigh, upper arm or abdomen
Pros & cons
Pros
  • SG label: dosing time can flex, min 8 h between doses
  • SG label: registered in SG at 100 u/ml and 200 u/ml
  • US label: u-100 pen gives up to 80 units per injection
Cons
  • US label: hypoglycaemia may be life-threatening
  • US label: hypokalaemia may be life-threatening
  • SG label: not for insulin pumps, and never given iv
Sources
  1. HSA — Listing of Registered Therapeutic Products (data.gov.sg dataset d_767279312753558cbf19d48344577084), Forensicclassification column; all 5,511 rows cached at /tmp/hsa_all.json and filtered locally (not re-fetched), 27 Aug 2026 · read 2026-08-27
    what it says
    “TRESIBA FLEXTOUCH PRE-FILLED PEN 100 U/ML SIN15703P and 200 U/ML SIN15704P, Insulin Degludec, ATC A10AE06, both Prescription Only; RYZODEG FLEXTOUCH 100 U/ml SIN15706P, Insulin Aspart&&Insulin Degludec, ATC A10AD06, Prescription Only”
  2. MOH National Drug Formulary (Singapore) — TRESIBA FLEXTOUCH 100 U/ML [SIN15703P], product information · read 2026-08-27
    what it says
    “INSULIN DEGLUDEC - 100 UNITS/ML … Registration Number SIN15703P … Licence Holder NOVO NORDISK PHARMA (SINGAPORE) PTE LTD … Forensic Classification PRESCRIPTION ONLY MEDICINES … ATC code A10AE06”
  3. MOH National Drug Formulary (Singapore) — TRESIBA [SIN15703P], Therapeutic indications · read 2026-08-27
    what it says
    “Treatment of diabetes mellitus in adults and adolescents from the age of 12–17 years”
  4. MOH National Drug Formulary (Singapore) — TRESIBA [SIN15703P], Posology · read 2026-08-27
    what it says
    “a basal insulin for once-daily subcutaneous administration at any time of the day, preferably at the same time every day … a dose of 1–80 units per injection … A minimum of 8 hours between injections should always be ensured”
  5. MOH National Drug Formulary (Singapore) — TRESIBA [SIN15703P], Method of administration · read 2026-08-27
    what it says
    “Tresiba is for subcutaneous use only … must not be administered intravenously … must not be used in insulin infusion pumps … administered subcutaneously by injection in the thigh, the upper arm or the abdominal wall”
  6. TRESIBA (insulin degludec) injection — US prescribing information, openFDA drug label record (Novo Nordisk), Indications · read 2026-08-27
    what it says
    “TRESIBA is a long-acting human insulin analog indicated to improve glycemic control in patients 1 year of age and older with diabetes mellitus … Not recommended for the treatment of diabetic ketoacidosis”
  7. TRESIBA (insulin degludec) injection — US prescribing information, Dosage and Administration: device ceilings · read 2026-08-27
    what it says
    “The FlexTouch pen delivers doses in 1 unit increments and can deliver up to 80 units in a single injection … TRESIBA U-200 … can deliver up to 160 units in a single injection”
  8. TRESIBA (insulin degludec) injection — US prescribing information, Warnings and Precautions · read 2026-08-27
    what it says
    “Never share a TRESIBA FlexTouch pen, insulin syringe, or needle between patients, even if the needle is changed … Hypoglycemia: May be life-threatening … Hypokalemia: May be life-threatening … Fluid retention and heart failure with concomitant use of Thiazolidinediones”
  9. TRESIBA (insulin degludec) injection — US prescribing information, Contraindications · read 2026-08-27
    what it says
    “TRESIBA is contraindicated: During episodes of hypoglycemia … In patients with hypersensitivity to insulin degludec or any of the excipients in TRESIBA”
  10. TRESIBA (insulin degludec) injection — US prescribing information, Drug Interactions (Table 5) · read 2026-08-27
    what it says
    “Drugs That May Increase the Risk of Hypoglycemia … ACE inhibitors, angiotensin II receptor blocking agents … fibrates, fluoxetine … salicylates … Drugs That May Decrease the Blood Glucose Lowering Effect … corticosteroids, danazol, diuretics, estrogens … thyroid hormones”
Report a correction View as JSON

Updated 2026-08-29. Every line above traces to a numbered source. Kozen-X is not a medical device and does not give medical advice. It lists what published sources have written down — nothing more. A pair not listed is unrecorded, not cleared. Before you start, stop or re-time anything, talk to your doctor or pharmacist.